Copied
 
 
2022, DKK
08.05.2023
Bruttoresultat

318''

Primær drift
Na.
Årets resultat

-371''

Aktiver

3.460''

Kortfristede aktiver

1.071''

Egenkapital

1.751''

Afkastningsgrad

0 %

Soliditetsgrad

51 %

Likviditetsgrad

98 %

Resultat
08.05.2023
Årsrapport
2022
08.05.2023
2021
25.04.2022
2020
04.05.2021
2019
07.05.2020
2018
25.04.2019
2017
16.04.2018
2016
01.06.2017
2015
22.05.2016
Nettoomsætning2.245.303.0001.792.626.0002.042.515.0002.346.296.0001.890.464.0001.897.063.0001.475.168.0001.215.664.000
Bruttoresultat318.378.000-46.989.000361.330.000873.518.000576.673.000528.294.000521.830.000364.177.000
Resultat af primær drift0000000-15.565.000
Indtægter af kapitalandele (tilknyttede og associerede) 00000000
Finansielle indtægter16.351.00021.826.00039.858.00034.905.00014.497.00079.072.0009.136.0001.666.000
Finansieringsomkostninger-133.797.000-54.005.000-49.088.000-85.138.000-70.202.000-18.828.000-35.844.000-89.047.000
Andre finansielle omkostninger00000000
Resultat før skat00-136.555.0000000-102.946.000
Resultat-371.486.000-503.090.000-115.666.000390.722.000-74.912.00091.002.00033.769.000-74.009.000
Forslag til udbytte00000000
Aktiver
08.05.2023
Årsrapport
2022
08.05.2023
2021
25.04.2022
2020
04.05.2021
2019
07.05.2020
2018
25.04.2019
2017
16.04.2018
2016
01.06.2017
2015
22.05.2016
Kortfristede varebeholdninger499.268.000506.458.000476.384.000425.809.000402.324.000323.905.000329.995.000272.528.000
Kortfristede tilgodehavender fra salg og tjenesteydelser 571.306.000803.320.0001.228.143.0001.175.208.000988.228.000989.483.000770.851.000336.353.000
Likvider323.00046.0002.317.0002.347.00027.907.00048.296.000198.316.000665.000
Kortfristede aktiver1.070.897.0001.309.824.0001.706.844.0001.603.364.0001.418.459.0001.361.684.0001.299.162.000609.546.000
Immaterielle aktiver og goodwill133.895.000163.816.000178.980.000204.615.000212.215.000412.645.000389.355.000419.182.000
Finansielle anlægsaktiver1.658.376.0001.660.133.0001.658.827.000313.503.000313.597.000361.338.000354.338.000342.787.000
Materielle aktiver597.079.000599.926.000546.292.000530.086.000482.224.000385.688.000364.089.000322.006.000
Langfristede aktiver2.389.350.0002.423.875.0002.384.099.0001.048.204.0001.008.036.0001.159.671.0001.107.782.0001.083.975.000
Aktiver3.460.247.0003.733.699.0004.090.943.0002.651.568.0002.426.495.0002.521.355.0002.406.944.0001.693.521.000
Aktiver
08.05.2023
Passiver
08.05.2023
Årsrapport
2022
08.05.2023
2021
25.04.2022
2020
04.05.2021
2019
07.05.2020
2018
25.04.2019
2017
16.04.2018
2016
01.06.2017
2015
22.05.2016
Forslag til udbytte00000000
Egenkapital1.750.675.0002.082.735.0002.621.030.0001.391.325.0001.007.124.000850.770.000758.845.000729.235.000
Hensatte forpligtelser54.557.00062.669.00079.116.00080.315.00060.952.00040.640.00067.832.00061.994.000
Langfristet gæld til banker0000000145.000.000
Anden langfristet gæld13.596.0000011.971.0003.260.0006.277.00010.661.00015.150.000
Leverandører af varer og tjenesteydelser169.305.000120.596.000130.100.000148.257.00078.808.00078.895.00077.882.00072.989.000
Kortfristede forpligtelser1.095.429.000908.545.000691.308.000618.315.000815.515.000800.597.0001.003.564.000424.603.000
Gældsforpligtelser1.655.015.0001.588.295.0001.390.797.0001.179.928.0001.358.419.0001.629.945.0001.580.267.000902.292.000
Forpligtelser1.655.015.0001.588.295.0001.390.797.0001.179.928.0001.358.419.0001.629.945.0001.580.267.000902.292.000
Passiver3.460.247.0003.733.699.0004.090.943.0002.651.568.0002.426.495.0002.521.355.0002.406.944.0001.693.521.000
Passiver
08.05.2023
Nøgletal
08.05.2023
Årsrapport
2022
08.05.2023
2021
25.04.2022
2020
04.05.2021
2019
07.05.2020
2018
25.04.2019
2017
16.04.2018
2016
01.06.2017
2015
22.05.2016
Afkastningsgrad Na.Na.Na.Na.Na.Na.Na.-0,9 %
Dækningsgrad 14,2 %-2,6 %17,7 %37,2 %30,5 %27,8 %35,4 %30,0 %
Resultatgrad -16,5 %-28,1 %-5,7 %16,7 %-4,0 %4,8 %2,3 %-6,1 %
Varelagerets omsætningshastighed 4,5 3,5 4,3 5,5 4,7 5,9 4,5 4,5
Egenkapitals-forretning -21,2 %-24,2 %-4,4 %28,1 %-7,4 %10,7 %4,5 %-10,1 %
Payout-ratio Na.Na.Na.Na.Na.Na.Na.Na.
Gældsdæknings-nøgletal Na.Na.Na.Na.Na.Na.Na.-17,5 %
Soliditestgrad 50,6 %55,8 %64,1 %52,5 %41,5 %33,7 %31,5 %43,1 %
Likviditetsgrad 97,8 %144,2 %246,9 %259,3 %173,9 %170,1 %129,5 %143,6 %
Resultat
08.05.2023
Gæld
08.05.2023
Årsrapport
08.05.2023
Nyeste:01.01.2022- 31.12.2022(offentliggjort: 08.05.2023)
Information om virksomhedens regnskabsklasse:The Annual Report of Xellia Pharmaceuticals ApS for the period January 1 - December 31, 2022 have been prepared in accordance with the provisions of the Danish Financial Statements Act applying to large enterprises of reporting class C. The Annual Report is presented in TDKK.
Beretning
08.05.2023
Beskrivelse af usikkerhed ved indregning eller måling:Recognition and measurement uncertainties The recognition and measurement of items in the Annual Report is not subject to any material uncertainties that could significantly impact the Annual Report.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:The Executive Board and Board of Directors have today considered and adopted the Annual Report of Xellia Pharmaceuticals ApS for the financial year January 1 – December 31, 2022.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Business review Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing, and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections. Xellia is a global leader in providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions. Xellia has an extensive history in developing, manufacturing, and commercializing anti-infective products, including Active Pharmaceutical Ingredients (APIs) as well as Finished Dosage Forms (FDF), where the majority are injectable drug products. As an organization, Xellia is committed to providing security and consistency of supply of critical care therapies. Through a global vertically integrated supply chain, the company continuously works to improve supply security through multiple sources of in-house production of its APIs and drug products, and in conjunction through working alongside Xellia’s R&D center. Supplying products to more than 70 countries worldwide and with more than 500 customers internationally, Xellia is the leading supplier of the important anti-infectives vancomycin, daptomycin, bacitracin, and colistimethate sodium (CMS). Through innovation and with the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Headquartered in Copenhagen, Denmark, Xellia has a global footprint with manufacturing, R&D and commercial operations across Europe, Asia, the Middle East and North America. Xellia’s four manufacturing facilities located in; China, Denmark, Hungary, and in the U. S. Xellia operates according to current Good Manufacturing Practice (cGMP), and Xellia’s facilities have been inspected by relevant regulatory health authorities, including the U. S. Food and Drug Administration (FDA). Xellia operates via two pillars, Global Anti-Infectives (‘GAI’) and US Injectables (‘USI’), which are defined by sales channels. Both businesses are supported by the quality assurance, supply and distribution, and R&D teams. The Global Antiinfective unit includes B2B (business to business) sales in all geographic markets and oversight of the three plants in Copenhagen, Budapest, and Taizhou. In addition to supporting current customers, the GAI organization works to introduce the company’s core product portfolio into new markets – where primary focus is in China, the Middle East and Latin America. The US Injectables business encompasses the handling of all sales in the US institutional market and the responsibility for US subsidiary production plant. The business unit is focused on the launch and commercialization of Xellia's own branded specialty injectable anti-infective medicines and generic products to the US institutional markets and also overseeing contract manufacturing operations for the US market. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of more than 1,800 people. Further information about Xellia can be found at: www. xellia. com
Vi bruger cookies til at øge oplevelsen og målrette vores markedsføring.
Ved at klikke OK tillader du brug af cookies. Læs mere her.
OK